Sun Pharma: Unloxcyt® Gains Category 2A Status In NCCN Guidelines For Patients With Advanced Skin Cancer Not Suitable For Surgery Or Radiation.

 20 Oct 2026 06:24 PM

Sun Pharma: Unloxcyt® Gains Category 2A Status In NCCN Guidelines For Patients With Advanced Skin Cancer Not Suitable For Surgery Or Radiation.

Sun Pharmaceutical Industries: Board Greenlights ₹10,000 Crore Non-Convertible Debentures And Mr. Gautam Doshi Steps Down As Non-Executive Independent Director Immediately.

 12 Oct 2026 08:00 PM

Sun Pharmaceutical Industries: Board Greenlights ₹10,000 Crore Non-Convertible Debentures And Mr. Gautam Doshi Steps Down As Non-Executive Independent Director Immediately.

Sun Pharma: Bernstein on Sun Pharma Maintains Outperform, Target Price ₹2,235; Leqselvi now has the clinical credentials to compete with Eli Lilly in alopecia, with market evidence suggesting convenience and label breadth alone do not determine leadership; expects Leqselvi to approach a US$300mn US run-rate by FY29E, with prescription inflection over FY27–29.

 08 Oct 2026 08:54 AM

Sun Pharma: Bernstein on Sun Pharma Maintains Outperform, Target Price ₹2,235; Leqselvi now has the clinical credentials to compete with Eli Lilly in alopecia, with market evidence suggesting convenience and label breadth alone do not determine leadership; expects Leqselvi to approach a US$300mn US run-rate by FY29E, with prescription inflection over FY27–29.

Sun Pharmaceutical Industries: Board Will Meet on October 12 to Discuss a Potential NCD Issue of Up to ₹15,000 Crore Through Private Placement.

 07 Oct 2026 08:41 PM

Sun Pharmaceutical Industries: Board Will Meet on October 12 to Discuss a Potential NCD Issue of Up to ₹15,000 Crore Through Private Placement.

Update On Pharma Co's: Sc Seeks Uniform 16% Retail Markup Cap On Medicines, Flags Wide MRP-PTR Gap - Newspaper

 30 Sep 2026 09:07 AM

Update On Pharma Co's: Sc Seeks Uniform 16% Retail Markup Cap On Medicines, Flags Wide MRP-PTR Gap - Newspaper

Sun Pharma: Macquarie on Sun Pharma Maintains Outperform, Target Price ₹2,150; PCSK9 inhibitor received European Commission approval on 21 September 2026, with Sun Pharma to make upfront, milestone and royalty payments under the licensing agreement; the deal expands its cardiovascular therapy presence by leveraging Organon’s platform and creates additional cross-selling opportunities.

 29 Sep 2026 09:01 AM

Sun Pharma: Macquarie on Sun Pharma Maintains Outperform, Target Price ₹2,150; PCSK9 inhibitor received European Commission approval on 21 September 2026, with Sun Pharma to make upfront, milestone and royalty payments under the licensing agreement; the deal expands its cardiovascular therapy presence by leveraging Organon’s platform and creates additional cross-selling opportunities.

Sun Pharma: 360 ONE Capital on Sun Pharma Maintains Buy, Target Price ₹2,250; Lerodarcil licensing deal strengthens the innovative-medicines portfolio, providing access to a US$3.7bn market outside the US and China that is growing at 38% CAGR, while supporting the scaling of the Organon acquisition.

 29 Sep 2026 09:01 AM

Sun Pharma: 360 ONE Capital on Sun Pharma Maintains Buy, Target Price ₹2,250; Lerodarcil licensing deal strengthens the innovative-medicines portfolio, providing access to a US$3.7bn market outside the US and China that is growing at 38% CAGR, while supporting the scaling of the Organon acquisition.

Sun Pharma: Co. Gets Global Ex-us & China Rights To Lerodalcibep From Lib Therapeutics, Strengthens Innovative Cardiovascular Portfolio

 28 Sep 2026 09:18 AM

Sun Pharma: Co. Gets Global Ex-us & China Rights To Lerodalcibep From Lib Therapeutics, Strengthens Innovative Cardiovascular Portfolio

Sun Pharma: Subsidiaries Resolve US Generic Drug Pricing Antitrust Case For A Secret Amount, Not Admitting Fault.

 11 Sep 2026 08:06 PM

Sun Pharma: Subsidiaries Resolve US Generic Drug Pricing Antitrust Case For A Secret Amount, Not Admitting Fault.

Sun Pharma: Bernstein on Sun Pharma Outperform, Target Price ₹2,235, as Moody’s Baa1/Stable and S&P preliminary BBB+/Stable ratings validate the thesis that combined cash flows can service the full $11.75bn Organon acquisition debt while sustaining R&D, manufacturing and shareholder returns; sees ~$1bn synergies over 3–4 years, with FY27–29 likely limited dividends/buybacks and FY28 focus on CEO-led integration, synergy extraction and supply-chain integration.

 11 Sep 2026 09:08 AM

Sun Pharma: Bernstein on Sun Pharma Outperform, Target Price ₹2,235, as Moody’s Baa1/Stable and S&P preliminary BBB+/Stable ratings validate the thesis that combined cash flows can service the full $11.75bn Organon acquisition debt while sustaining R&D, manufacturing and shareholder returns; sees ~$1bn synergies over 3–4 years, with FY27–29 likely limited dividends/buybacks and FY28 focus on CEO-led integration, synergy extraction and supply-chain integration.

GLP-1 Weight-loss Boom Pushes Pharma Companies Into Nutraceuticals And Wellness, Opening New Growth Avenues - Newspaper

 10 Sep 2026 09:08 AM

GLP-1 Weight-loss Boom Pushes Pharma Companies Into Nutraceuticals And Wellness, Opening New Growth Avenues - Newspaper

Sun Pharma: Co. Incorporates Unit "Sun Pharma Global Treasury Centre IFSC Limited" In Gift City, Gandhinagar; Entity To Operate As Global Treasury Centre For Sun Pharma Group.

 09 Sep 2026 03:01 PM

Sun Pharma: Co. Incorporates Unit "Sun Pharma Global Treasury Centre IFSC Limited" In Gift City, Gandhinagar; Entity To Operate As Global Treasury Centre For Sun Pharma Group.

Sun Pharmaceutical Industries: Plans Meetings With Analysts and Investors On September 10, 16, and 17

 03 Sep 2026 04:22 PM

Sun Pharmaceutical Industries: Plans Meetings With Analysts and Investors On September 10, 16, and 17

Sun Pharma: Secures 2-year Us Tariff Relief In Mfn Drug-pricing Deal

 02 Sep 2026 09:14 AM

Sun Pharma: Secures 2-year Us Tariff Relief In Mfn Drug-pricing Deal

Sun Pharma: Bernstein on Sun Pharma Maintains Outperform with Target Price of ₹2,235 as the MFN agreement protects and expands its US$1.2–1.3bn innovative-medicines franchise, potentially improving patient access and biologic adoption through lower Medicaid pricing and reduced authorization barriers.

 02 Sep 2026 08:43 AM

Sun Pharma: Bernstein on Sun Pharma Maintains Outperform with Target Price of ₹2,235 as the MFN agreement protects and expands its US$1.2–1.3bn innovative-medicines franchise, potentially improving patient access and biologic adoption through lower Medicaid pricing and reduced authorization barriers.

Sun Pharma: HSBC on Sun Pharma Maintains Buy with Target Price of ₹2,120 as the MFN deal removes the tariff overhang for two years, with limited estimated FY29 EPS impact and further clarity awaited.

 02 Sep 2026 08:43 AM

Sun Pharma: HSBC on Sun Pharma Maintains Buy with Target Price of ₹2,120 as the MFN deal removes the tariff overhang for two years, with limited estimated FY29 EPS impact and further clarity awaited.

Sun Pharma: Supports White House's Medicine Access Push With Most Favored Nation Pricing For US Medicaid, Deferring Section 232 Tariffs And Acquiring Organon For $11.75 Billion To Boost US Market Growth.

 01 Sep 2026 07:35 AM

Sun Pharma: Supports White House's Medicine Access Push With Most Favored Nation Pricing For US Medicaid, Deferring Section 232 Tariffs And Acquiring Organon For $11.75 Billion To Boost US Market Growth.

India Govt Seeks Joint Ventures With Japanese Companies In Pharma And Shipbuilding, Says Goyal

 27 Aug 2026 11:09 AM

India Govt Seeks Joint Ventures With Japanese Companies In Pharma And Shipbuilding, Says Goyal

Sun Pharma: Gets Positive Ruling From Appellate Court In Lipitor Antitrust Case, Upholding Summary Judgment For Company And Its Subsidiaries.

 17 Aug 2026 09:04 AM

Sun Pharma: Gets Positive Ruling From Appellate Court In Lipitor Antitrust Case, Upholding Summary Judgment For Company And Its Subsidiaries.

Sun Pharma: Co Faces Delhi High Court Challenge For Semaglutide Tablet Launch, Court Orders Approval Before Selling After Novo Nordisk's Patent Infringement Claim. - Newspaper

 12 Aug 2026 09:02 AM

Sun Pharma: Co Faces Delhi High Court Challenge For Semaglutide Tablet Launch, Court Orders Approval Before Selling After Novo Nordisk's Patent Infringement Claim. - Newspaper